World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
32086
World Ranking
12145
National Ranking
6231

Overview

Miloslav Beran is affiliated with The University of Texas MD Anderson Cancer Center in the United States. The institution is recognized for its medical research and cancer treatment focus, which provides a contextual backdrop for Beran's professional scope.

There are no recorded recent papers attributed to Miloslav Beran in the available data, nor are there listed frequent co-authors or venues of publication. This limits specific insights into the detailed research outputs or collaborative networks associated with the scientist.

The data does not include information about book publications, main scholarly fields, subfields of study, or principal topics of research. Additionally, there are no awards documented in relation to Beran's career, so any distinctions or recognitions remain unreported.

Given the lack of detailed publication and thematic data, this profile focuses on the known institutional affiliation, which may imply an orientation towards clinical or biomedical research activities related to cancer or related medical fields at MD Anderson. The absence of further research details suggests either unpublished or undisclosed work, or involvement in professional roles not captured by standard academic publication metrics.

Best Publications

  • Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

    Bruce D. Cheson;Peter L. Greenberg;John M. Bennett;Bob Lowenberg

  • Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

    Sergio Giralt;Elihu Estey;Maher Albitar;Koen Van Besien

  • Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

    Kelly Moran-Crusio;Linsey Reavie;Alan Shih;Omar Abdel-Wahab

  • Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia

    Hagop M Kantarjian;Susan O'Brien;Terry L. Smith;Jorge E Cortes

  • Report of an international working group to standardize response criteria for myelodysplastic syndromes

    B. D. Cheson;J. M. Bennett;Hagop M Kantarjian;A. Pinto

  • Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

    Omar Abdel-Wahab;Ann Mullally;Cyrus Hedvat;Guillermo Garcia-Manero

  • Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

    B. Douglas Smith;Mark Levis;Mark Levis;Miloslav Beran;Miloslav Beran;Francis Giles;Francis Giles

  • Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

    Hagop Kantarjian;Deborah Thomas;Susan O'Brien;Jorge Cortes

  • Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

    Deborah A. Thomas;Stefan Faderl;Jorge Cortes;Susan O'Brien

  • Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia

    William Wierda;Susan O'Brien;Sijin Wen;Stefan Faderl

  • Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.

    M. J. Keating;S. O'Brien;S. Lerner;C. Koller

  • Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy

    Hagop M. Kantarjian;Terry L. Smith;Susan O'Brien;Miloslav Beran

  • Results of the Fludarabine and Cyclophosphamide Combination Regimen in Chronic Lymphocytic Leukemia

    Susan M. O’Brien;Hagop M. Kantarjian;Jorge Cortes;Miloslav Beran

  • Expression of the Wilms' tumor gene (WT1) in human leukemias.

    H Miwa;M Beran;G F Saunders

  • JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome–negative CML, and megakaryocytic leukemia

    Jaroslav Jelinek;Yasuhiro Oki;Vazganush Gharibyan;Vazganush Gharibyan;Vazganush Gharibyan;Carlos Bueso-Ramos

  • Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

    William G. Wierda;Susan O'Brien;Xuemei Wang;Stefan Faderl

  • Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients

    Francesco Onida;Hagop M. Kantarjian;Terry L. Smith;Greg Ball

  • Results of Fludarabine and Prednisone Therapy in 264 Patients With Chronic Lymphocytic Leukemia With Multivariate Analysis-Derived Prognostic Model for Response to Treatment

    Susan O'Brien;Hagop Kantarjian;Miloslav Beran;Terry Smith

  • Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.

    E Estey;P Thall;M Andreeff;M Beran

  • Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.

    Michael J. Keating;Susan O'Brien;Hagop Kantarjian;William Plunkett

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Elihu H. Estey
Elihu H. Estey University of Washington
Jorge E. Cortes
Jorge E. Cortes Augusta University
Francis J. Giles
Francis J. Giles Northwestern University
Michael J. Keating
Michael J. Keating The University of Texas MD Anderson Cancer Center
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Stefan Faderl
Stefan Faderl The University of Texas MD Anderson Cancer Center
Sherry Pierce
Sherry Pierce The University of Texas MD Anderson Cancer Center
Deborah A. Thomas
Deborah A. Thomas The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Medicine in the USA opens up a range of online degrees and career pathways that can expand your opportunities in the healthcare field. In addition to the traditional medical track, you can consider complementary degrees that are highly valued in today’s healthcare landscape.

For those interested in the business and management side of healthcare, the cheapest online master degree in healthcare administration provides essential leadership skills for running medical organizations. Nurses looking to advance their clinical expertise might explore the best online dnp programs to achieve a Doctor of Nursing Practice degree and increase their leadership potential.

Pharmacy remains a high-demand field, and earning a pharmacy degree online can prepare you for a career in medication management, research, or patient care. Additionally, managing health data is a critical part of today’s system, and accredited him programs (Health Information Management) can qualify you for specialized roles in medical records and informatics.

These flexible, affordable online programs offer alternative ways to build a rewarding healthcare career, whether you’re looking to specialize, lead, or support medical teams.

Best Scientists Citing Miloslav Beran